PRRX2 and cancer: Inhibition of PRRX2 was previously correlated with lower expression of genes controlling epithelial-mesenchymal transition, a process linked to cancer progression (57), specially through inactivation of Wnt/β-catenin pathway (58) — a hallmark of ACP.